"Utilizing point-of-care tests for cardiac biomarkers may be considered a valuable addition to the interpretation of postmortem changes that may be used for the further development of forensic pathology. The point is that it was evident from the cases described in this study that processes caused by trauma or some cardiovascular events and the application of separate tests such as cardiac troponin I and creatine kinase-myocardial band may help in evaluating the situation more carefully and distinguishing their signs. The advantages of using such testing in postmortem examination are to make the information about the cause of death more defined and the value of complementing the limitations in time that are observed when evaluating gross or histopathology data made during the terminal event. In this way, it is possible to state that the recent development in diagnostics presents an advantage for those cases where timely information is required to make a decision and the new postmortem diagnostic tool is needed to use in forensic pathology for a more detailed evaluation of the case."

While most tested HbA1c methods [Afinion 2, HbA1c 501 (both utilizing boronate affinity), QuikRead go, cobas b 101, DCA Atellica] show minimal bias, the Standard F immunoassay exhibits a clinically significant interference with Hb Tacoma, resulting in a 38% mean relative bias (17 mmol/mol). This discrepancy likely stems from conformational changes in the variant affecting the assay's two-antibody design. Given the regional prevalence of Hb Tacoma, these findings highlight the necessity of selecting variant-robust methods to ensure accurate glycemic monitoring and patient safety.

This study assessed 17 point-of-care (CRP) tests, revealing that quantitative devices significantly outperform semi-quantitative ones. While QuikRead go and Spinit showed the highest accuracy and strongest correlation with reference standards, semi-quantitative tests suffered from poor reliability in intermediate ranges and subjective interpretation issues. The researchers conclude that quantitative tests are the most effective tool for guiding antibiotic use and clinical decision-making in decentralized settings.

"We compared the performance of STANDARD F S. pneumoniae Ag FIA with that of BinaxNOW S. pneumoniae Antigen Card using 206 urine samples. The performance of STANDARD F was highly comparable to that of BinaxNOW. STANDARD F assay could be a valuable tool for diagnosis of invasive pneumococcal disease."

The study compared the ID NOW (a rapid NAAT) with three digital LFIAs: BD Veritor Plus, STANDARD F, and ichroma TRIAS. While ID NOW demonstrated superior sensitivity, the digital LFIAs - particularly the ichroma TRIAS - proved to be efficient, high-throughput alternatives suitable for large-scale clinical testing.

"The STANDARD™ F Analyzer showed variable analytical performance, with limited analytical comparability to reference methods, particularly for hs-CRP and at low cTnI concentrations. Categorical agreement was moderate overall, but clinically relevant misclassifications were observed. Therefore, the POCT platform may serve as a complementary tool in settings without immediate access to a core laboratory, provided that its analytical limitations are recognized and results are interpreted using assay-specific thresholds."

"The HbA1C method on the STANDARD F2400® Analyzer displayed performance characteristics that are consistent with manufacturer specifications and are above industry standard quality for a point-of-care device for HbA1C. These suggest that may be used to support routine monitoring of persons with diabetes mellitus in Nigeria."

"The diagnostic performance of STANDARD™ F H. pylori Ag FIA (SD Biosensor) has proved to be an alternative to the chemiluminiscence antigenic test used in our population. The STANDARD™ F H. pylori Ag FIA (SD Biosensor) on the STANDARD™ F2400 analyzer is a highly sensitive, specific and suitable assay for the detection of H. pylori in stool samples. The results have shown almost perfect concordance with the LIAISON® H. pylori SA assay. In addition, it also saves sample handling and working time as no sample pre-treatment is required."